How Preclinical Manufacturing Can De-Risk the Path to GMP-Ready Viral Vector Programs

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 08 Oct, 20:45 UTC

In this GEN webinar, Chris Nieder, an expert in viral vector programs, will examine how strategically designed preclinical manufacturing campaigns provide a practical foundation for GMP production. The post How Preclinical Manufacturing Can De-Risk the Path to GMP-Ready Viral Vector Programs…

science

Sources

• T2How Preclinical Manufacturing Can De-Risk the Path to GMP-Ready Viral Vector ProgramsFierce Biotech / Fierce Healthcare / MedCity / GEN08 Oct, 20:45